M. Bhave

发表

Racial Disparities in Clinical Outcomes on Investigator-Initiated Breast Cancer Clinical Trials at an Urban Medical Center.

M. Rupji, M. Torres, K. Kalinsky, 2022, Clinical breast cancer.

A phase I/II study of the combination of temozolomide (TM) and pazopanib (PZ) in advanced pancreatic neuroendocrine tumors (PNETs) (NCT01465659).

A. Rademaker, J. Berlin, A. Benson, 2018 .

Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx

Rachel M. Lee, C. Arciero, Manali A. Bhave, 2019, Annals of Surgical Oncology.

Challenges of multiple mutations in individual patients with haemophilia

K. Ghosh, S. Shetty, Manali A. Bhave, 2011, European journal of haematology.

Acquired hemophilia a: diagnosis, aetiology, clinical spectrum and treatment options.

K. Ghosh, S. Shetty, Manali A. Bhave, 2011, Autoimmunity reviews.

An update on the risk prediction and prevention of anticancer therapy-induced cardiotoxicity

S. Rosen, Manali A. Bhave, Ami N. Shah, 2014, Current opinion in oncology.

Cardiovascular toxicity of biologic agents for cancer therapy.

S. Rosen, Manali A. Bhave, Nausheen Akhter, 2014, Oncology.

Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events

J. Feinglass, H. Te, L. VanWagner, 2012, Hepatology.

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

S. Loi, M. Burkard, R. Bose, 2023, Annals of Oncology.

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

Corinne Miller, Alfred Rademaker, Young Kwang Chae, 2018, Oncotarget.

Spatially variant immune infiltration scoring in human cancer tissues

S. Ramalingam, A. F. Coşkun, Y. Gökmen-Polar, 2022, npj Precision Oncology.

Extended Endocrine Therapy: Is 5 Years Enough?

N. Henry, Manali A. Bhave, N. L. Henry, 2017, Current Oncology Reports.

Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy

Y. Chae, Manali A. Bhave, L. Park, 2020, Translational lung cancer research.

Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients.

Y. Chae, Manali A. Bhave, J. Anker, 2018, Cancer treatment reviews.

A Tale of 3 Tracers: Contrasting Uptake Patterns of 18F-Fluciclovine, 68Ga-PSMA, and 18F-FDG in the Uterus and Adnexa.

D. Schuster, G. Ulaner, I. Lawal, 2022, Clinical nuclear medicine.

Monitoring of Triple Negative Breast Cancer After Neoadjuvant Chemotherapy.

J. Aldrich, Madison Canning, M. Bhave, 2023, Clinical breast cancer.

Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early‐stage Breast Cancer

K. Kidwell, S. Murphy, Cindy Alsamarraie, 2017, Clinical breast cancer.

Pharmacological suppression of the OTUD4-CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.

W. Gradishar, Yifan Xue, Junlong Chi, 2024, The Journal of clinical investigation.

A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.

K. Yonemori, M. Beeram, S. Estrem, 2022, Journal of Clinical Oncology.